> top > docs > PubMed:15788693 > annotations

PubMed:15788693 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET

Id Subject Object Predicate Lexical cue
T0 1098-1101 gene:1048 denotes CEA
T1 953-960 disease:C0016629 denotes fowlpox
R1 T0 T1 associated_with CEA,fowlpox

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
15788693-5#104#107#gene1048 907-910 gene1048 denotes CEA
15788693-5#158#161#gene1048 961-964 gene1048 denotes CEA
15788693-5#295#298#gene1048 1098-1101 gene1048 denotes CEA
15788693-5#150#157#diseaseC0016629 953-960 diseaseC0016629 denotes fowlpox
104#107#gene1048150#157#diseaseC0016629 15788693-5#104#107#gene1048 15788693-5#150#157#diseaseC0016629 associated_with CEA,fowlpox
158#161#gene1048150#157#diseaseC0016629 15788693-5#158#161#gene1048 15788693-5#150#157#diseaseC0016629 associated_with CEA,fowlpox
295#298#gene1048150#157#diseaseC0016629 15788693-5#295#298#gene1048 15788693-5#150#157#diseaseC0016629 associated_with CEA,fowlpox

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 134-1224 OBJECTIVE denotes Cancer vaccines targeting tumor-associated antigens are being investigated for the therapy of tumors. Numerous strategies, including the direct intratumoral (i.t.) vaccination route, have been examined. For tumors expressing carcinoembryonic antigen (CEA) as a model tumor-associated antigen, we previously designed poxviral vectors that contain the transgenes for CEA and a triad of T-cell costimulatory molecules, B7-1, intercellular adhesion molecule-1, (ICAM-1), and leukocyte function associated antigen-3 (LFA-3) (CEA/TRICOM). Two types of poxvirus vectors were developed: replication-competent recombinant vaccinia and replication-defective recombinant fowlpox. We have shown previously that a vaccine regimen composed of priming mice s.c. with recombinant vaccinia-CEA/TRICOM and boosting i.t. with recombinant fowlpox-CEA/TRICOM was superior to priming and boosting vaccinations using the conventional s.c. route in inducing T-cell responses specific for CEA. These studies also showed that CEA was needed to be present both in the vaccine and in the tumor for therapeutic effects.
T2 1246-1479 METHODS denotes To determine specific immune responses associated with vaccination-mediated tumor regression, CEA-transgenic mice bearing CEA(+) tumors were vaccinated with the CEA/TRICOM s.c./i.t. regimen, and T-cell immune responses were assessed.
T3 1489-1999 RESULTS denotes In CEA(+) tumor-bearing mice vaccinated with the CEA/TRICOM s.c./i.t. regimen, T-cell responses could be detected not only to CEA encoded in vaccine vectors but also to other antigens expressed on the tumor itself: wild-type p53 and an endogenous retroviral epitope of gp70. Moreover, the magnitude of CD8(+) T-cell immune responses to gp70 was far greater than that induced to CEA or p53. Finally, the predominant T-cell population infiltrating the regressing CEA(+) tumor after therapy was specific for gp70.
T4 2012-2167 CONCLUSIONS denotes These studies show that the breadth and magnitude of antitumor immune cascades to multiple antigens could be critical in the therapy of established tumors.